STALLERGENES-GREER
18.5.2020 09:07:12 CEST | Business Wire | Press release
Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the expansion of the supply of subcutaneous products (SCIT), further broadening its offering to patients and the medical community through a sustained investment in quality and operational excellence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200518005223/en/
“Stallergenes Greer is committed to the disciplined execution of the company’s strategy and is well advanced on its transformation journey. Our robust fundamentals, investments in quality, and commitment to operational excellence continue to yield results as evidenced by the expansion of SCIT products, the widening of our portfolio and the solidifying of our leadership positions in various markets. We can be proud of our achievements and look ahead with confidence,” declares Michele Antonelli, Chief Executive Officer.
Acceleration of SCIT production
In April 2020, the French Agency for Medicines and Health (ANSM) lifted its injunction, which primarily impacted the production of subcutaneous products for the Europe and International region. SCIT production will fully resume in Antony, France, in the coming weeks, starting with skin prick tests (Alyostal® pricks) for diagnosis, and Alustal® for the treatment of patients with allergies. SCIT production in the US, where Stallergenes Greer continues to lead the market, has remained fully operational and was not part of the injunction.
With sustained investments in its global manufacturing capabilities, Stallergenes Greer operates state-of-the-art manufacturing and quality systems that meet the highest product quality standards.
Stallergenes Greer intends to further provide injectable forms with the resumption of Phostal®.
SCIT products meet the needs of patients whose profile and lifestyle require an alternative access to treatment and delivery mode, longer intervals between treatment, or monitoring of adherence by their physician.
Further broadening the allergen immunotherapy treatment portfolio
Stallergenes Greer remains determined to offer an extensive portfolio of treatment solutions tailored to each patient profile and to each market, including injectable therapies, sublingual therapies such as drops and tablets, venoms and diagnostics. From diagnosis to treatment, Stallergenes Greer’s portfolio is designed to ensure the consistency of its products in terms of active ingredients and high-quality standards. It allows physicians to choose the administration method which is best suited to each patient’s needs and lifestyle.
In 2019 alone, the company added 15 new Staloral® allergen references to its sublingual portfolio and will launch another 10 references in 2020.
Stallergenes Greer, also continued to enhance its tablet offering which already includes Oralair® for the treatment of grass pollen allergies and Actair® for the treatment of house dust mite allergies, which is distributed in selected countries of the Asia-Pacific region.
The company recently submitted a European marketing application authorisation for its house dust mite allergy immunotherapy tablet. The tablet is also under New Drug Submission review by Health Canada.
Stallergenes Greer is delivering on the disciplined execution of its strategy of providing people with allergies a broad range of personalised treatment options, which will make it both a company with a complete portfolio and a valued partner for patients and the medical community.
ABOUT STALLERGENES GREER Ltd
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
Additional information is available at https://www.stallergenesgreer.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005223/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SPIE Awards $351,000 in Scholarships to 85 Students Shaping the Future of Optics and Photonics28.5.2026 20:15:00 CEST | Press release
Annual scholarship program builds foundation for photonics industry’s next generation SPIE, the international society of optics and photonics, announced awarding $351,000 in scholarships that will provide support to 85 SPIE Student Members studying optics, photonics, or a related field. The scholarships range from $3,000 to $11,000 and awardees are selected by the SPIE Scholarship Committee from a roster of applicants. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528142502/en/ “I am deeply passionate about advancing the inclusion of women and other underrepresented groups in the fields of optics and photonics, which makes it especially meaningful to be recognized as a recipient,” said Alana Gonzales, who received a $10,000 Women in Optics Scholarship. “Being able to apply this scholarship toward tuition, fees, and essential academic expenses such as books and electronics will both ease the financial burden of the final
Rubedo’s RLS-1496 Reduces Actinic Keratosis Pre-Cancerous Skin Lesions by 46% at Four Weeks with Minimal Irritation in Preliminary Results of Phase 1b/2a Study28.5.2026 14:30:00 CEST | Press release
RLS-1496 is an investigational, first-in-class, disease-modifying, selective glutathione peroxidase 4 (GPX4) modulator that targets pathologic senescent and other stressed, aging cells that drive chronic, age-dependent diseases, such as AK, and represents a novel drug category — Adaptive SenoTherapeutics In recognition of May as Skin Cancer Awareness Month, Rubedo is calling attention to the myths and facts surrounding AKs — and to the urgent need for a new generation of treatments that are effective without the side-effect burden of today's options Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a Phase 1b/2a study of RLS-1496 in patients with actinic keratosis (AK), a common age-related condition resulting in precancerous skin lesions, that is most commonly seen after age 65.1 The open-label multi-center trial, conducted in the United States,
ExaGrid Wins 5 Industry Awards at Network Computing Awards 202628.5.2026 14:00:00 CEST | Press release
ExaGrid named “Company of the Year” for seventh year in a row ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that company was honored with five industry awards, including Air-gapped Ransomware Recovery Product of the Year, Bench Tested Product of the Year, Company of the Year, Data Protection Product of the Year, and the Storage Product of the Year during the Network Computing Awards ceremony, held in London on May 21, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528849813/en/ The ExaGrid team headed to the stage five times throughout the Network Computing Awards ceremony in London to accept awards for ExaGrid Tiered Backup Storage. Photo courtesy of Network Computing Awards. The Network Computing Awards are determined by public vote. The 2026 awards mark
Ardoq Launches AI-First Enterprise Architecture Platform28.5.2026 14:00:00 CEST | Press release
Custom Agents, Omnipresent AI Assistant, and AI Import Builder Automate an Estimated 40% of Routine EA Work; Tenneco Already Achieving 292% ROI on Ardoq AI Ardoq, named a 5x Leader in the Gartner® Magic Quadrant™ for Enterprise Architecture Tools, today launched its AI-first enterprise architecture (EA) platform. The release grounds every Ardoq AI output in customers' live architecture data and introduces a new generation of AI agents capable of automating an estimated 40% of routine EA work. Architects today are being asked to defend decisions that generic AI is generating in seconds. Application rationalization choices. ERP transformation roadmaps. AI governance reviews. The questions land on the architect's desk, but the analysis underneath increasingly comes from AI assistants that do not know the architecture. Generic agents reason on whatever document is in front of them, not on the live relationships between applications, dependencies, capabilities, and risks. Ask a generic LLM
European DataWarehouse Launches DealDox®, a Next-Generation Virtual Data Room Built specifically for the Securitisation Market28.5.2026 14:00:00 CEST | Press release
European DataWarehouse (EDW) announced today the launch of DealDox®, a secure virtual data room uniquely tailored to the needs of the securitisation and structured finance market. Developed in response to long‑standing challenges around transaction data and document management, DealDox provides a single, secure environment where all parties throughout the deal lifecycle can collaborate efficiently while maintaining high standards of security, governance, and regulatory alignment. DealDox enables the centralised management of transaction data and documentation, offering robust security, granular access controls, and clear audit trails. The platform integrates seamlessly with EDW’s existing regulatory reporting ecosystem, supporting smoother workflows from deal preparation through to disclosure and compliance. “As a market infrastructure, our role is to reduce complexity and make processes simpler and more transparent for all participants,” said Dr. Christian Thun, CEO of European DataWa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom